

## PATENT COOPERATION TREATY

PCT

NOTICE INFORMING THE APPLICANT OF THE  
COMMUNICATION OF THE INTERNATIONAL  
APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

To:

BAZZICHELLI, Alfredo  
Società Italiana Brevetti S.p.A.  
Piazza di Pietra, 39  
I-00186 Roma  
ITALIE

RICEVUTO

26 MAR. 2000

SOCIETA' ITALIANA BREVETTI S.p.A.  
Piazza di Pietra 39  
00186 ROMADate of mailing (day/month/year)  
18 May 2000 (18.05.00)Applicant's or agent's file reference  
RM/X89418/PC

IMPORTANT NOTICE

International application No.  
PCT/IT99/00356International filing date (day/month/year)  
08 November 1999 (08.11.99)Priority date (day/month/year)  
06 November 1998 (06.11.98)

Applicant

ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE et al

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:  
AU,CN,JP,KP,KR,MA,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

AE,AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,CA,CH,CU,CZ,DE,DK,EA,EE,EP,ES,FI,GB,GD,GE,GH,GM,  
HR,HU,ID,IL,IN,IS,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,NZ,OA,PL,PT,  
RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,TZ,UA,UG,UZ,VN,YU,ZA,ZW

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on  
18 May 2000 (18.05.00) under No. WO 00/28060.

## REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

## REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

J. Zahra

Facsimile No. (41-22) 740.14.35

Telephone No. (41-22) 338.83.38

## PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 23 June 2000 (23.06.00)	
International application No. PCT/IT99/00356	Applicant's or agent's file reference RM/X89418/PC
International filing date (day/month/year) 08 November 1999 (08.11.99)	Priority date (day/month/year) 06 November 1998 (06.11.98)
Applicant COLLOCA, Stefano	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

26 May 2000 (26.05.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Olivia RANAIVOJAONA
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>RM/X89418/PC</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/IT 99/ 00356</b>	International filing date (day/month/year) <b>08/11/1999</b>	(Earliest) Priority Date (day/month/year) <b>06/11/1998</b>
Applicant <b>ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

## 4. With regard to the title,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

**CELLS FOR THE PRODUCTION OF HELPER DEPENDENT ADENOVIRAL VECTORS**

## 5. With regard to the abstract,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.



because the applicant failed to suggest a figure.




because this figure better characterizes the invention.

1



None of the figures.



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

14

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference RM/X89418/PC-EBR	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/IT99/00356	International filing date (day/month/year) 08/11/1999	Priority date (day/month/year) 06/11/1998
International Patent Classification (IPC) or national classification and IPC C12N15/86		
Applicant ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 7 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  26/05/2000	Date of completion of this report  08.03.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Lanzrein, M  Telephone No. +49 89 2399 7358  

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IT99/00356

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

### Description, pages:

1-43 as originally filed

### Claims, No.:

1-27 as originally filed

### Drawings, sheets:

1/2-2/2 as originally filed

### Sequence listing part of the description, pages:

1-6, filed with the letter of 11.02.00

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IT99/00356

- ☐ the description,      pages:
- ☐ the claims,      Nos.:
- ☐ the drawings,      sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims	1-21
	No:	Claims	22-27
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-27
Industrial applicability (IA)	Yes:	Claims	1-27
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

## VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/IT99/00356

1. Reference is made to the following documents:

D1: WO 98 13510 A (PARKS ROBIN ;CHEN LIANE (CA); GRAHAM FRANK L (CA)) 2 April 1998 (1998-04-02)

D2: FR-A-2 738 575 (CENTRE NAT RECH SCIENT) 14 March 1997 (1997-03-14)

D3: WO 98 13499 A (CIBA GEIGY AG ;SCRIPPS RESEARCH INST (US); MEMEROW GLEN R (US); VO) 2 April 1998 (1998-04-02)

**D1** describes a helper virus where the packaging signal ( $\Psi$ ) is flanked by loxP sites, allowing for excision in a cre-expressing cell. Furthermore, the helper virus is deficient in pIX, a capsid-stabilizing protein, resulting in a packaging constraint. Because only sequences smaller than 35 kb are packaged, the helper virus DNA, which is larger, is not packaged.

**D2** discloses cell lines which complement for E1 and E4 functions. The E4 non-structural proteins are expressed under the control of a functional promotor, which is optionally inducible (p. 5, lines 22-30).

**D3** discloses packaging cell lines expressing the adenovirus fiber protein and containing the E1 or E4 sequences. The fiber and E1/E4 DNA sequences were introduced via separate plasmids (p. 5, third paragraph; example 1C). D3 teaches the use of inducible promoters (p. 5, lines 4-5; p. 25-26).

The adenoviral vector is deleted in the corresponding regulatory E1/E4 genes and the structural gene coding for the fiber protein (other structural proteins are contemplated, p. 4-5).

2. The present application concerns cells for the production of helper dependent adenoviral vectors. The cells contain a defective adenoviral genome where  $\Psi$  and a nonstructural region (E1, E4) are inactivated. The inactivated nonstructural region is complemented by a second genic unit where said region is under the

control of an inducible promotor. Thus, the cell, upon activation of the promotor expresses all nonstructural and structural adenoviral genes. The cells allow thus the packaging helper dependent, "gutless" adenoviral vectors, i.e. vectors which carry only the minimal sequences needed for replication and encapsidation, whereas all the other viral genes have been deleted.

The examples describe how the cell lines were constructed. However, no data are provided concerning production efficiency of the helper dependent virus and the ratio of helper dependent virus to helper virus produced (i.e the contamination with helper virus).

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Claims 22-27 lack novelty in the sense of Art. 33 (2) EPC.
  - 1.1 Claim 22 lacks novelty in view of D1. The helper virus of D1 has a deletion in E1 and lacks  $\Psi$  in a cre-expressing cell.
  - 1.2 Claim 23 lacks novelty in view of D2 or D3, as both documents describe cells containing the E1 or E4 genes under control of inducible promoters.
  - 1.3 Claim 26 is not novel in view of D1, which provides another system for production of helper virus dependent adenoviral vectors. The vectors produced therewith are essentially free of helper-virus contamination.
  - 1.4 Claims 24, 25, 27 lack novelty insofar as referring to claims 22 or 23.
2. Claims 1-21 appear to be novel over the cited prior art.



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/IT99/00356

3. Claims 1, 26 and appending claims 2-25, 27 are objected under Art. 33 (3) PCT due to lack of inventive step.

Claim 1 can be understood in the sense that cells are claimed which are able to produce helper-dependent, "gutless" adenoviral vectors without producing contaminating helper virus (see below item VIII, 1.). However, such cells are not disclosed. The applicants have not shown experimentally that the cells described in the specification indeed produce viral particles that are free of helper virus contaminants. It is conceivable that some DNA of the first genic unit is packaged into virions despite the inactivation of  $\Psi$ , and this will lead to production of helper virus.

The technical problem underlying the present alleged invention can be seen the provision of a cell producing helper-free vectors. The solution to this problem is not disclosed, since the technical effect (i.e. the production of helper-free vector) has not been experimentally substantiated. The cells disclosed may not exhibit the desired technical effect. Under these circumstances, inventive step cannot be acknowledged.

In order to avoid the inventive step objection under Art. 33 (3) PCT, claim 1, 26 needs clarification (see item VIII, 1.).

**Re Item VI**

**Certain documents cited**

**Certain published documents (Rule 70.10)**

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 00/12740	09. 03. 00	27. 08. 99	28. 08. 98

**R. It m VIII**

**Certain observations on the international application**

1. Claim 1, 26 (and appending claims) lack clarity within the meaning of Art. 6 PCT and are not enabled (Art. 5 PCT).

Claim 1 recites that the cells "enable the production of said helper dependent defective adenoviral in said cells in absence of helper".

This can be understood in two different ways:

- i) There is no helper virus needed for production of the vector
- ii) The cells produce only helper-dependent defective adenoviral particles, without any contamination of helper virus

If the claim is understood according to ii), the subject-matter is not sufficiently supported by the description and not enabled, because the application provides no data are concerning production efficiency of the helper dependent virus and the ratio of helper dependent virus to helper virus produced, i.e the contamination with helper virus (cf. item V, 3.).

2. Claims 18-21 are objected under Art. 6 PCT because the subject-matter for which protection is sought is unclear. The expression "partially constituted by the genome of a human adenovirus" is unlimited and the claim therefore covers cells wherein the first unit consists of anything else than adenoviral DNA. Therefore, the subject-matter for which protection is sought is not precisely defined and is not clearly distinguishable from the prior art in the sense of Art. 33 (2) PCT.
3. Claim 25 refers to human cells, whereby embryonic cells are not excluded. The description refers to adenovirus permissible cells, the classical cell line being HEK 293 of embryonic origin. It is thus at present not clear whether the scope of protection could be as broad as extending to genetic manipulation of the human germline or to human embryonic stem cells and thereby to chimeric and transgenic animals/humans. In case of later regional filings, the claim may have to be restricted in order to comply with rules referring to public morality.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 99/00356

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/86 C12N5/10 C07K14/075

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 13510 A (PARKS ROBIN ; CHEN LIANE (CA); GRAHAM FRANK L (CA)) 2 April 1998 (1998-04-02) page 7, line 33 - page 9, line 36; claims 1,2,6,9,16,19 page 25, line 2133	1,2,8,9, 18-27
A	FR 2 738 575 A (CENTRE NAT RECH SCIENT) 14 March 1997 (1997-03-14)  claims 1-7,9,10,15-22	1,10,11, 17-21, 23-27
A	WO 98 13499 A (CIBA GEIGY AG ; SCRIPPS RESEARCH INST (US); MEMEROW GLEN R (US); VO) 2 April 1998 (1998-04-02) the whole document	1,9-14
	---	
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

30 June 2000

Date of mailing of the international search report

06/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

# INTERNATIONAL SEARCH REPORT

Int. onal Application No

PCT/IT 99/00356

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E ➤	<p>WO 00 12740 A (AMALFITANO ANDREA ; HU            HUIMIN (US); UNIV DUKE (US); CHEN YUAN            TSONG) 9 March 2000 (2000-03-09)            claims            1-3, 78-81, 85, 207-213, 217, 218, 223-228, 231, 2            32            -----</p>	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 99/00356

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9813510 A	02-04-1998	EP 0938579 A	01-09-1999
FR 2738575 A	14-03-1997	AU 717253 B	23-03-2000
		AU 4544396 A	07-08-1996
		BR 9606971 A	04-11-1997
		CA 2210168 A	25-07-1996
		CZ 9702306 A	15-10-1997
		EP 0805868 A	12-11-1997
		FI 973055 A	18-07-1997
		WO 9622378 A	25-07-1996
		HU 9702404 A	28-04-1998
		JP 11504502 T	27-04-1999
		NO 973332 A	18-07-1997
		SK 99097 A	04-02-1998
WO 9813499 A	02-04-1998	AU 4624197 A	17-04-1998
		EP 0937150 A	25-08-1999
WO 0012740 A	09-03-2000	AU 5694299 A	21-03-2000

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 7 : C12N 15/86, 5/10, C07K 14/075	A2	(11) International Publication Number: <b>WO 00/28060</b> (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/IT99/00356 (22) International Filing Date: 8 November 1999 (08.11.99) (30) Priority Data: RM98A000694 6 November 1998 (06.11.98) IT (71) Applicant (for all designated States except US): ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE [IT/IT]; P. Angeletti S.p.A., Via Pontina Km. 30,600, I-00040 Pomezia (IT). (72) Inventor; and (75) Inventor/Applicant (for US only): COLLOCA, Stefano [IT/IT]; Via Peretti, 22, I-00153 Roma (IT). (74) Agents: BAZZICHELLI, Alfredo et al.; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published Without international search report and to be republished upon receipt of that report.

(54) Title: CELLS FOR THE PRODUCTION OF HELPER DEPENDENT ADENOVIRAL VECTORS, METHOD FOR THE PREPARATION AND USE THEREOF


## (57) Abstract

The present invention relates to cells that can be used for the production of helper dependent adenoviral vectors in absence of further helpers, as they contain genic units capable of expressing the functions necessary for the completion of the viral cycle that are absent in such vectors. The present invention further includes the method for the production of said cells, the use thereof for the production of adenoviral vectors.


A)




B)



C)



D)



*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

CELLS FOR THE PRODUCTION OF HELPER DEPENDENT ADENOVIRAL  
VECTORS, METHOD FOR THE PREPARATION AND USE THEREOF

DESCRIPTION

FIELD OF THE INVENTION

5       The present invention relates to the field of gene therapy and in particular to the use and the development of vectors of viral origin and of cell lines for the production thereof.

BACKGROUND OF THE INVENTION

10       An important aspect in the development of the gene therapy is the development of vectors capable of introducing genetic material into the target cells. In order to be effective, those vectors are required to possess several features: they must be capable of  
15       accommodating large or multiple transgenes, inclusive of gene regulation elements, yet remaining simple to manipulate, such as to enable the production thereof on a pharmaceutical scale. Moreover, it is essential that they be safe and of a low toxicity, though preserving the  
20       capability of introducing the transgenes in an efficient and selective manner into the target tissues. Finally, the vector should preferably be compatible with an appropriate retention, expression and regulation of the transgene into the target cell.

25       At present, the adenovirus-based viral vectors seem to be the ones most suitable for manipulations making them capable of meeting all of those requirements. To date they are considered the most effective system for the introduction of heterologous genes in mammalian  
30       cells, both *in vivo* and in cells cultivated *in vitro* (Hitt M.M. et al.1997. Advances in Pharmacol.40, 137-206).

35       This is due to some interesting characteristics of the Adenoviruses (Ad), which constitute a DNA virus family (the ones infecting the human beings have been classified in 57 serotypes), characterised by an icosahedral capsid lacking an outer coat: they are highly



- 2 -

infective but relatively innocuous, primarily infect  
hepitolial cells but can also infect cells of other  
tissues, regardless of their being in active replication  
phase. Because of their high infectiousness in vitro of  
5 cell lines of human origin, they can easily be produced  
in large amounts. Moreover, it has been proved that human  
DNA inserts can be efficiently transferred into  
hepitolial human cells through Ad infection (Horvitz,  
"Adenoviridae and their replication" in Virology, Field  
10 and Knipe, ed. Raven Press, NY; 1990; pages 1679-1740).

With regard to molecular biology of the virus,  
adenovirus, in particular the human one, has a linear  
double-stranded DNA genome, of about 36kb, functionally  
subdivided into two regions, non-structural and  
15 structural. The first one includes regions encoding  
polypeptides expressed in the first stages of the  
infection, i.e., prior to the viral DNA replication (E  
regions), the second ones includes regions coding for  
polypeptides expressed in the subsequent stages of the  
20 viral cycle (L region). Following the infection of a  
competent cell, when the viral DNA reaches the nucleus,  
the first region to be transcribed is the E1a region  
coding for proteins involved in the transactivation of  
the other regions, both E and L, of the viral DNA. The  
25 subsequently transcribed E1b region encodes proteins  
regulating the RNA synthesis, both viral and of the host  
cell, and protecting the latter from the apoptotic effect  
otherwise exerted by E1a. Therefore, the E1a/E1b  
functions are essential for the viral replication.

30 The E2 region encodes proteins directly involved in  
the viral replication, like the viral DNA-polymerase, the  
pre-terminal protein and proteins binding to the viral  
DNA. The E3 region encodes proteins that are unnecessary  
for the viral replication in cultured cells, but are  
35 involved, in vivo, in the regulation of the antiviral  
immune response. Lastly, the E4 region contains groups of  
genes whose products reduce the gene expression of the

- 3 -

host cell and increase the transcription of the E2 and L regions of the viral genome.

5 The L region of the viral genome essentially encodes proteins of structural type, or anyway involved in the assembling of the viral particles.

10 In the 40 years following the first isolation, following the characterisation of Ad viruses, the relevant modifications that made them efficient carriers for the transfer of genic material have been progressively get ready.

In particular the interventions on the Ad genome have been firstly carried out in order to:

- increase the capability of the viral genome to accept the insertion of heterologous genes;
- 15 - eliminate intracellular toxicity deriving from the expression of adenovirus genes.

Such interventions consist mainly in the provision of progressive deletions of viral regions, whose functions are provided in trans.

20 In a first generation vectors (derived from human Ad serotypes 2 and 5), the deletion has involved the E1-region, making the virus defective for the capability of replication, unless the proteins produced by such transcriptional unit are provided in trans.

25 An increase of the size of the etherologous gene to be inserted and the restriction of the propagation of the recombinant viruses in cell lines that complement such defect because they constitutionally express genes of the viral E1 region, have bee obtained.

30 However, the deletion of E1 is not sufficient *per se* to completely eliminate the expression of other genes of the E and L regions, and to prevent the viral DNA replication. It follows that in animals infected with those vectors the presence of viral antigens and the  
35 onset of immune responses aiming at the destruction of the infected cells are detected (Yang et al. Proc. Natl Acad Sci. 91:4407-4411; 1994). This leads to the loss of

- 4 -

the gene of therapeutic interest and to the onset of inflammatory reactions. Moreover, the persistence of an immunological memory of these reactions can greatly diminish the effectiveness of a second administration of an adenoviral vector of this type (Kozarsky et al. J. Biol. Chem. 269:1-8; 1994).

Hence new, second generation, adenoviral vectors carrying different combinations of early gene deletion have been constructed to improve the safety profile of Adenoviral vectors. Vectors differently combining E1, E2, E3, and/or E4 deletion have been demonstrated to be less cytotoxic *in vitro* and more stable in mouse liver than the classic  $\Delta$ E1 first generation vectors (Gao, G-P. 1996 J.Virol. 70:8934-8943; Dedieu, J-F. 1997 J.Virol. 71:4626-4637; Gorziglia, M.I. 1996 J.Virol. 70:4173-4178; Amalfitano, A. 1998 J.Virol. 72:926-933). *In vitro* experiments demonstrated that such deletions effectively diminished, but not abolished, the toxicity.

In addition, vectors carrying additional deletions further increasing the capability of the viral genome to accept the insertion of heterologous genes have been produced (Englehardt et al. Proc. Natl Acad Sci. 91:6196-6200; 1994; Bett et al. Proc. Natl Acad Sci. 91:8802-8806; 1994; Yeh, P., et al. 1996 J. Virol. 70:559-565). However, the maximum capacity of a first generation adenoviral vector does not exceed 8 kb, whereas that of a  $\Delta$ E1/E3/E4 vector reaches 11 kb and the foreign genes can be equally inserted in the region E1 or E3.

In this context, following the discovery that a minimal portion, about 600 bp, of the viral DNA is strictly necessary for the replication and the encapsidation of recombinant vectors, totally defective adenoviral vectors, and consequently totally depending on the presence of helper viruses for the replication and the assembling thereof in viral particles, have been developed.

Such kind of helper-dependent adenoviral vectors

- 5 -

(AdHD) carry minimal Ad sequences containing the signals sufficient for the replication and the encapsidation. All the other factors necessary for virion production are provided in trans by a helper virus. The helper genome is constructed in such a manner that its sequences containing encapsidation signals can be easily eliminated in vivo through the use of specific recombination systems like the cre/lox system (WO97/32481).

Accordingly, the relevant strategies for the preparation of helper-dependent Adenovirus virions (adenoHD) are essentially based on the use of three elements:

- cell lines transformed so as to make them capable of expressing the genes encoding the group of adenovirus E1 proteins, and a recombinase, usually "cre";
- a helper adenovirus wherein the E1 region is deleted and wherein the viral DNA sequences required for the encapsidation thereof inside the mature virion are flanked by recombination sites acting as substrates for the recombinase ("loxP" in case of "cre");
- the adenoHD vector carrying the transgene of interest.

Although representing a remarkable improvement over the strategies utilising first generation vectors, this strategy presents some problems. For a production on a pharmaceutical scale, the requirement of controlling three independent components (the cell line, the helper and the transgenic vector) entails difficulties that are hard to overcome and unacceptable production costs.

Firstly, the cre-type recombinases catalyze both the deletion and the insertion of the DNA regions flanked by the loxP sites. The excision reaction is normally up to 20-fold more efficient than the opposite one, however a complete removal of the helper from the viral production can never be obtained. This is unacceptable especially in the pharmaceutical practice, and helper contamination of preparations of therapeutical use is a really serious

- 6 -

problem.

A second limitation of this type of strategy is due to the difficulty of optimising the quantitative ratios between helper virus and helper-dependent virus during the amplification process. Hence, the vector amplification seldom approaches the efficiency of first generation vectors, and more often yields lesser to the extent of one order of magnitude are obtained. As in the previous case, this problem is dramatic when a production on an industrial scale is required, the costs becoming practically prohibitive.

In order to solve the problem deriving from the helper virus contamination and to reduce the number of components, an alternative strategy known in the art is that of engineering cell lines to make them capable of expressing all the factors necessary for the encapsidation of the defective virus, eliminating hence the helper virus.

In prior art there are several description of cells expressing one or more viral proteins (see for instance Wo98/13499). Such-cell lines can be used for the production of adenoviral vectors defective of the complementary viral proteins. However according to these strategy it is extremely difficult to satisfactorily produce the exact co-ordination of the events between the viral DNA replication and the expression of the structural proteins that in the natural infection lead to the massive production of viral particle typical of the lytic phase. Accordingly, adopting these strategies, the viral cell cycle cannot be mimicked. In absence of this, only a limited yielding capacity may be achieved.

#### SUMMARY OF THE INVENTION

Object of the present invention is a helper cell line enabling the production of helper dependent adenoviral vectors in total absence of any kind of helper virus. Such a cell line has been in fact constructed in order to make all the essential functions for the Ad

- 7 -

virus replication to be contained in the cells, splitted in particular in two genic units allowing a strictly regulated expression thereof.

5 The first genic unit comprises at least one defective Ad genome having the Inverted Terminal Repeats (ITRs) in head-to-tail configuration, and having the encapsidation signal and at least one of the non-structural regions inactivated.

10 Such non-structural regions can be expressed regions, or cys-acting elements. The expressed regions can be both not-translated non-structural genes, like for instance the VA ones, or translated non-structural genes like the E1, E2 and E4 genes.

15 In a preferred embodiment the inactivation is carried out by totally, or more preferably by partially, deleting at least one of such regions; the encapsidation signal as well is preferably inactivated by total or partial deletion.

20 Such a first genic unit can be located on an episomal unit or can be integrated in the genome of the host cells.

In the first case, the episomal unit must comprise at least one element enabling the replication of the episomal unit itself at a low number of copies. Such  
25 element can be constituted by sequences mediating DNA replication and its retention in the nucleus (Calos MP. 1996 Trends Genet 12: 463-466), or by the origin of replication of the origin of replication system of a virus, activated by at least one activating factor.

30 The origin of replication must be in any case located on the episomal unit; the activating factor instead can be introduced inside the cell or the relevant gene can be located on the episomal unit including the first genic unit (or in any other replicating unit inside  
35 the cell), or can be integrated in the genome of the host cell. In any case the gene coding for the activating factor inside the cells of the present invention shall be

- 8 -

expressed in order to allow the replication of the first genic unit in the episomal unit.

5 An example of origin of replication system functional for the present invention, is the relevant system of Epstein-Barr virus (which is the preferred one), wherein the origin of replication is the OriP element and the activating factor is EBNA-1 protein. However also different systems like the one of bovine papilloma virus (BPV) (Calos MP, (1998) Proc Natl Acad Sci USA 95:4084), or those taken from vectors based on SV40 origin-T antigen system, are suitable as well.

15 The presence of such origin of replication system allows the first genic unit to replicate at low number of copies, while the ITRs in the first genic unit allow the replication at high number of copies in presence of the proteins coded by the E2 regions.

20 In case instead the first genic unit is integrated in the genome of the host cells, ITRs sequences must be present in head-to-tail configuration in both the extremities of the first unit. Such ITRs in fact enable the rescue and the replication of the first genic unit at high number of copies in presence of the regulatory proteins encoded by the above mentioned genes of E2 regions.

25 In any case regulatory elements controlling the expression of at least one of the non-structural regions in the first unit, can be further comprised in such a first genic unit or can however be present in the cell, preferably integrated in the cell genome.

30 An example of such regulatory elements are the elements described by Rittner (Rittner K., et al (1997) J. Virol. 71:3307-3311),

35 The second genic unit includes an inducible transcription unit which comprises the viral non-structural regions inactivated in the Ad defective genome of the first genic unit, under the control of a strictly regulation-responsive inducible promoter. Such regions

- 9 -

can be for example E1, E2 and/or E4.

5 An inducible promoter in the units object of the present invention, and in particular in the second genic unit, is a promoter induced by an inductor. An example is given by the tetracycline promoter, which is the preferred one, even if promoter regulated by the presence of other inductors like ecdysone, rapamycin, RU486, dexametasone or heavy metal like Zn or Cd, are suitable as well.

10 Such a promoter can be operatively linked to regulatory elements like tetracycline-responsive transactivators and/or silencers (rtTA and tTS), both enabling the tight regulation of the transcription unit.

15 The second genic unit can be introduced in the host cell by a vector which can be viral or plasmidic, can be integrated in the genome of the host cell, or can be present on an episomal unit, in any case must be kept inactive during the growth phase of the cell line to avoid the cytotoxic effect of the viral proteins. At this purpose specific regulatory element enabling the specific repression of said transcription unit can be included in the second genic unit. An example of such a repressor is the Tet/krab fusion protein.

20 Such repressor elements are in any case functionally co-ordinated with the inducible promoter and with the regulatory element enhancing the expression of the transcription unit described above.

25 In absence of the inductor acting on the relevant inducible promoter of the second genic unit (transcription unit) in fact, the non-structural regions contained therein are not expressed, the first genic unit is inactive and there is no production of viral protein toxic for the cell.

30 For starting the production of the helper dependent adenoviral vector, the helper cell line is infected with the helper dependent adenoviral vector that is to be produced in large amounts, and in the meantime (but also



- 10 -

before or after the infection with the defective adenoviral vector) the inductor of the inducible promoters of the second gene unit present in the cell is added, or its expression inside the cell is induced.

5       The result of such action will be the production of the adenoviral proteins coded by the early regions included in the second genic unit, entailing the activation of the transcriptional cascade of adenoviruses associated to the ITR-mediated replication of the first  
10       genic unit.

      The consequence of this co-ordinated series of events is the accumulation of large amounts of structural proteins of the virus, similar to what occurs during the natural infection. The viral proteins are sequestered in  
15       the construction of the viral particle and results consequently in the efficient production of the helper-dependent viral vector.

      In this connection it shall be pointed out that for the purpose of the present invention an helper dependent  
20       adenoviral vector is an Adenoviral vector whose viral cycle cannot be completed in absence of an helper, in particular adenoviral vector wherein the viral genome has been totally or partially deleted with the exception of the packaging signal and the inverted terminal repeats  
25       (ITRs). For the purpose of the present invention they are also denominated herein after and before, as helper dependent adenovirus or helper dependent adenovirus virions.

      Essentially, this strategy aims at mimicking the  
30       phenomenon of the viral latency: in the helper cell a viral genome is kept in a latent phase by suppression of the expression of genes underlying the adenovirus transcriptional cascade. At the moment of the infection/transformation with the defective adenoviral  
35       vector that is to be produced, the lytic phase is activated by inducing the expression of the proteins coded by the early genes deleted from the Ad genome

- 11 -

included in the first genic unit and put under tight transcription control in the second genic unit.

5 The previously latent adenoviral genome included in the first unit enters therefore in active replication and transcription, but only the helper dependent vector that is to be produced is packaged, as it only possesses an functional encapsidation signal.

10 As a consequence of the fact that the system object of the present invention include two instead of three elements, the helper dependent adenoviral vectors production is greatly facilitated, enabling, after a large scale preparation, a final yield of titer levels between  $10^9$  and  $10^{12}$  particle/milliliter. Such a property of the cell lines of the present invention is  
15 particularly relevant if applied in large scale productions like the one of the pharmaceutical industry. Accordingly the present invention enable an improved production of the vectors transferring therapeutical genes suitable in the treatment of human or veterinary  
20 diseases.

In any case, it has to be noted that the two genic element can be inserted in the cell in different times. Accordingly the cell lines containing at least the first genic element only, and cell lines containing at least  
25 the second genic element only, are a further object of the present invention. The second element in the first case and the first element in the second case, can in fact be added, before or contemporarily the transfection of the cell by the helper dependent adenoviral vector.

30 In connection with the subject matter disclosed above and below object of the present invention are therefore the cells useful in the production of helper dependent adenoviral vectors, characterised in that they include at least one of the following genic units:

35 - a first genic unit comprising an Adenovirus defective genome having the inverted terminal repeats sequences in head-to-tail configuration, and having both

- 12 -

the encapsidation signal and at least one of the non-structural regions, inactivated;

5       - a second genic units comprising at least one inducible promoter and at least one of the regions inactivated in the first genic unit, said regions being under the control of said inducible promoter;

10       whereby following the activation of the inducible promoter of the second genic unit and the infection of the cell with said helper dependent adenoviral vectors, the first genic unit and the second genic unit enable the production of said helper dependent defective adenoviral in said cells in absence of helper.

15       Further objects of the present invention are the cells above described wherein the first genic unit is integrated in the genome and the ITRs are present on the both extremities of said first unit in head-tail configuration; the cells above described wherein the first genic unit is comprised in an episomal unit including an element enabling the replication of said  
20       genic unit in a low number of copies. In the latter, particular cases are given by cells wherein said element enabling the replication of the episomal unit is, or is derived by, the origin of replication of the origin of replication system of a virus; the case wherein the  
25       relevant activating factor is introduced inside the cell from outside the cell; the cases wherein the gene coding for the activating factor is on the episomal unit or in other transcriptional unit inside the cell, or alternatively is integrated in host cell genome.

30       The origin of replication system described above can be the one of the Epstein-Barr virus (EBV) and the origin of the replication element is OriP and the activating factor is EBNA-1.

35       Further particular cases referred to each case above are the following: the case wherein the encapsidation signal and/or the non-structural regions of the first genic unit are totally or partially deleted; the case

- 13 -

wherein the regions inactivated in the first genic unit and present in the second genic unit is at least one of the early regions selected from the group consisting of E1, E2 and E4 regions, more particularly the case wherein  
5 said regions are E1 and E4, the case wherein said regions are E1 E4 and E2A, the case wherein said regions are E1 E4 and E2b polymerase, and the case wherein said regions are E1 E4 and E2b preterminal protein (PTP).

Further case are the ones wherein the viral region  
10 present in the first genic unit is operatively linked to at least one regulatory element enabling the tight control of their expression; cells in which particularly the promoter on the second genic unit is the tetracycline operator, the promoters regulated by steroid hormones  
15 receptors, the promoter regulated by ecdysone receptor, the promoter regulated by rapamycin, the promoter regulated by RU486, and the metallothioneine promoter regulated by metal ions; in these case the relevant inductors are constituted by tetracycline, ecdysone,  
20 rapamycin, dexametasone RU486 and a heavy metal like Zn or Cd respectively; cells in which the viral regions in the second genic unit are operatively linked to elements controlling the expression of the non-structural regions present thereon, and in particular the instance in which  
25 such elements is tetracycline-responsive transactivators and/or silencers; the cells in which at least one of the non-structural regions in the second genic unit are totally or partially derived from adenovirus genome, preferably human adenovirus, preferably AD2 or AD5  
30 serotype adenoviruses. In these latter cases, the different part of the non-structural regions present on the second genic unit can be derived from adenoviruses of the same serotype or from adenoviruses of a different serotype.

35 Further case of interest are constituted by the cells in which the adenovirus genome of the first genic unit is derived totally or partially from adenovirus

- 14 -

genome of mammalian adenoviruses, preferably human adenoviruses preferably AD2 and AD5 serotype adenovirus. In these latter cases, the different part of the adenovirus genome present on the first genic unit can be  
5 derived from adenoviruses of the same serotype or from adenoviruses of a different serotype.

The genic units of the present invention can be introduced in the cells in at least one vector, preferably plasmid, kept or not in episomal phase; both  
10 in case they are integrated in the host genome and they are present on a replicating unit inside the cell, such first and second genic units can be operatively linked, to genomic sequences ensuring the expression of the functions encoded by at least one of said units in a  
15 regulated manner.

Further object of the present invention are the cells including only the first genic unit and the cells including only the second genic unit.

Further, all the above described cells can be  
20 eukaryotic cells, preferably mammalian, preferably of humans, and in this latter case also preferably cells permissive for the Adenovirus replication. In particular A549 cell line (human lung carcinoma ATCC CLL 185) are suitable for the derivation of the cells of the present  
25 invention.

A further object of the present invention is a method for the production of the above-mentioned cells comprising the following steps:

- 30 a) introduction in a cell line of the first genic unit as described above;
- b) introduction in the cell line of step a) of second genic unit as described above.

Particular cases are represented by such a method wherein the first genic unit of step a) and the second  
35 genic unit of the step b) are introduced in a vector plasmidic or viral. With specific regard to the plasmidic vectors suitable for the present invention cloning

- 15 -

vectors like pUC, pBluescript and pLitmus, are to be considered.

With specific regard to the viral vectors suitable for the present invention, retroviral vectors, adeno  
5 associated virus vectors, herpes simplex vectors and Epstein-Barr virus derived vectors are to be considered.

Even such methods can be carried out, preferably, on a eukaryotic cell line of mammals, preferably on a human cell line and preferably on the A549 cell line  
10 (human lung carcinoma ATCC CLL 185).

Another object of the present invention is the use of the above-mentioned cells for the production of helper dependent adenoviral vectors, or the A549 cell line (human lung carcinoma ATCC CLL 185) both in vivo and in  
15 vitro.

A further object of the present invention is the use of the above-mentioned cells for the production of the helper dependent adenoviral vectors, according to the technique known in the art.

Such helper-dependent adenoviral vectors shall contain at least one gene, which can preferably be a gene of therapeutical interest, whose products in particular are useful in gene therapy, in particular aimed against human or veterinary illnesses. Particular case are the  
20 following the case wherein the helper-dependent adenoviral vectors include at least one gene of interest in genetic engineering processes or in processes for producing transgenic animals; the case wherein the products of the activity of said gene are peptides or  
25 ribozymes.

A further object of the present invention are also compositions comprising the helper dependent adenoviral vectors, in particular mammalian helper dependent adenoviral vectors, and a vehicle or a carrier, characterised in that said composition is from 99% to  
35 100% free of contaminating helper viruses.

Compositions comprising a vehicle or a carrier and

- 16 -

at least one of the cells described above, in particular the cases wherein the cells contain the first genic unit and/or the second genic unit or the case wherein the cells contain the first and the second genic units and the helper-dependent adenoviral vector, are object of the present invention. Such vehicle or carrier can be water, glycerol, ethanol, saline, or the like or the combinations thereof.

Particularly relevant cases are those wherein the vehicle or the carrier in all of these compositions are pharmaceutically acceptable and compatible with the active principle constituted by the above mentioned helper dependent adenoviral vector and/or at least one of the cells above described. Pharmaceutically acceptable carriers are the ones well known in the art, i.e. sterile aqueous solutions which can contain the active principle only or can further include buffer such sodium phosphate at physiological pH value, and/or physiological saline such as phosphate buffered saline. In addition other excipients like wetting or emulsifying agent, dissolution promoting agent, pH buffering agent, stabilisers and colorants, or the like of any of them, or any other additive known in the art are further included in such compositions.

In this connection pharmaceutically acceptable or compatible carriers or vehicles are referred to the materials known in the art capable of administration to or unto a subject, for example a mammal particularly a human being, without the production of undesirable physiological effect. An example of such effects is given by nausea, gastric upset, dizziness and the like.

The preparation of such compositions, which can be pharmaceutical or pharmacological compositions wherein the active principles are dissolved or dispersed therein, is well understood in the art. Generally such compositions are prepared for parenteral administration or in any case as injectable compositions, either as

- 17 -

liquid solutions or suspension. In any case solid forms suitable for solutions or suspension in liquid prior to use can be prepared. Preparations suitable for other desired routes of administration according to the technique well known in the art, like oral route, dermal patches, suppositories, or even also preparation emulsified, are included in the present invention.

Particular cases are provided by the compositions containing the helper-dependent adenoviral vector, or at least one of the cells of the present invention including helper-dependent adenoviral vectors, comprising at least one gene coding for molecules of therapeutical interest, molecules, which can be also peptides or ribozymes, in particular useful in gene therapy, more specifically aimed against human illnesses.

Object of the present invention is therefore also the use of the cells object of the present invention as a medicament and in particular for the preparation of the above mentioned compositions, in particular for the pharmaceutical or pharmacological compositions suitable in gene therapy.

A further object of the present invention is the process for the production of at least one of the compositions described above, that can be pharmaceutical compositions or matter compositions.

Further object of the present invention are kits comprising at least one of the compositions described above for the production of the helper dependent adenoviral vectors according to the present invention *in vitro*, *in vivo* or *ex vivo*. Of particular interest are the kit including:

- a composition comprising at least one of the cells described above including first genic unit the second genic unit and a helper dependent adenoviral vector;
- a composition comprising an inductor capable of activating the inducible promoter in the second genic unit;



- 18 -

Of particular interest is also the case wherein the kit includes:

- 5       - a composition comprising at least one of the cells described above including the first genic unit and the second genic unit;
- a composition comprising at least one helper dependent adenoviral vector including at least an etherologous gene, in particular of therapeutic interest; and optionally
- 10       - a composition comprising an inductor capable of activating the inducible promoter in the second genic unit.

15       The kits of the present invention can be kit for the therapeutic use (production *in vivo* or *ex vivo* of the helper dependent adenoviral vector comprising at least an gene of therapeutic interest, in particular in gene therapy) and kit for the production *in vitro* of helper dependent adenoviral vector containing at least one gene, preferably of therapeutic interest.

20       The invention will be better described with the aid of the annexed figures.

DESCRIPTION OF THE FIGURES

25       Figure 1 shows in the four boxes the schematic charts of vectors useful for deriving the helper cell lines of the present invention:

30       A) Chart of the AD5 shuttle vector (first genic unit): Ad5 $\Delta\Psi\Delta E1/E4$  represents the genome of a human adenovirus, complete except for deletion of the E1, E4 regions and of the one including the encapsidation signal ( $\Psi$ ); AdITRs the Ad5 ITRs genic sequences in head-tail configuration; Hygro<sup>r</sup> the hygromycin resistance gene; Amp<sup>r</sup> the ampicillin resistance gene; EBNA-1 the viral transactivator of the Epstein-Barr virus (EBV); and OriP represents the origin of latent replication of the EBV virus.

35       B) Chart of the E1/E4 vector (second genic unit): where E1 and E4 represent DNA sequences corresponding to

- 19 -

E1 and E4 adenovirus regions, MSC I and II are sequences including Multiple Cloning Sites, PminCMV are the minimal promoters of Citomegalovirus (CMV), TRE (Tetracycline Responsive Element) represents seven repeated sequences of the operator of the E. Coli tetracycline resistance gene;  $\beta$ -globin polyA is the polyadenylation site of the  $\beta$ -globin; ColE1ori is the E. Coli replication origin; SV40 polyA is the SV40 virus polyadenylation site.

C) Chart of the pTet-On/Off vector (regulatory element): where Pcmv and Psv40 are the promoters of CMV and SV40 respectively, (r)tTa indicates the controllable transactivator of tetracycline (or the inverted one, i.e., the one activated only by a tetracycline). This transactivator in turn consists of the gene coding for the tetracycline repressor (or its mutant rtetR of opposite function) fused to the VP16AD domain of the herpes simplex virus. Neo<sup>r</sup> represents the neomycin resistance gene.

D) Chart of the pTet-KRAB vector (regulatory element): essentially similar to the pTet-On/Off vector where the sequences coding for VP16AD domain of the herpes simplex virus are substituted with those of the KRAB domain of the Kox human gene.

Figure 2 shows the schematic charts of vectors useful for deriving the helper cell lines of the present invention:

A) Chart of the AD/EBV shuttle vector pSA-1 (first genic unit): Ad5 represents the genome of a human adenovirus, complete except for deletion of the E1, E4 regions and of the one including the encapsidation signal ( $\Psi$ ); AdITRs the Ad5 ITRs genic sequences in head-tail configuration; Hygro<sup>r</sup> the hygromycin resistance gene; Amp<sup>r</sup> the ampicillin resistance gene; OriP represents the origin of latent replication of the EBV virus; Tet eptamer represent an eptamer of tetracycline repressor DNA binding sites. The sequences of DNA that were deleted to generate different  $\Delta$ E2 version of this vector are also

- 20 -

indicated: DBP deletion represent the deletion of the entire coding sequence of the DNA binding protein; Polymerase deletion represent the deletion of 608 bp within the amino terminus of the polymerase gene; pTP deletion represent the deletion of two DNA segment within the main exon of preterminal protein gene.

B) Chart of the AD/EBV shuttle vector pSA-2 (first genic unit), the only element that differentiate pSA-2 from pSA-1 is the insertion of EBNA-1 gene beside OriP replication origin.

C) Chart of the pIREStTS/rtTA<sub>puro</sub> (regulatory element): where CMV IE represent human cytomegalovirus immediate-early promoter; rtTA represent DNA sequences corresponding Tetracycline reverse transactivator; IRES is the sequence including ribosome internal entry site; tTS-Kid represent the sequence corresponding to fusion between tet repressor and silencing domain of Kid-1; Kid-1 S domain is the silencing domain of Kid-1; SV40 PuroR polyA represent the puromycin resistance gene expression cassette; Amp is the ampicillin resistance gene.

#### DETAILED DESCRIPTION OF THE INVENTION

A first aspect of the present invention is the one referred to the construction and use of the first genic unit as described in the summary of the invention for the derivation of the helper cells of the present invention.

The first genic unit can be constructed as plasmid vector adopting the standard recombinant DNA techniques. Modification (insertions, deletions, mutation) of the first genic unit can be obtained according to the procedure described by A.F. Stuart and coworkers (Zhang et al. Nat. Genet. 1998; 20:123-128).

The first unit, when inserted in the genome of the host cell, typically includes:

i) an adenovirus genome, complete except for the deletion of at least one of the non-structural regions that are essential for the progress of Adenoviral transcriptional cascade and of the one including the

- 21 -

encapsulation signal;

ii) two sequences of Ad inverted terminal repeats (ITRs) in head-to-tail configuration flanking the Adenoviral genome; and generally also

5       iii) a marker of selection, like G418 resistance gene, Hygromycin B resistance gene, puromycin resistance gene, bleomycin resistance gene is present that can be used to select cell line that stably maintain the unit.

Cell lines containing the first genic unit  
10 integrated into the host chromosome can be obtained by transformation of the cell with the vector DNA using standard DNA transfection technique and cultivating the transformed cells in a selective medium (+ G418 or Hygromycin B or bleomycin or puromycin), according to the  
15 relevant techniques known in the art.

Transcription and replication of an adenoviral vector inserted in the host chromosome between two ITR junctions in head-to-tail configuration can be also activated supplying in trans viral factors deleted and/or  
20 the viral functions inactivated from the adenoviral genome using DNA transfection or infection with viral vectors or direct delivery of active viral polypeptides.

In the case instead, wherein the first genic unit is kept on an episomal unit the vector used for the  
25 introduction of the first unit has been denominated "shuttle vector" such a shuttle vector being a vector (plasmidic or viral) in an episomal form, and has been constructed in order to include the element reported in the point i) above, generally the element reported in the  
30 point iii) above and further comprising:

iv) the origin of the latent replication of a virus and in particular the Epstein-Barr virus (EBV);

v) the Ad inverted terminal repeats (ITRs) genic sequences in head-tail configuration;

35       The vector in this case has been denominated "Ad/EBV shuttle vector" due to the characterizing presence of the EBV elements. In a further embodiment in fact also the

- 22 -

gene coding for the protein EBNA-1 is included.

In a preferred embodiment of such vector the adenovirus genome of the point i) is deleted of E1 and E4 gene and E2 promoter basal activity is reduced by  
5 inserting a Tet silencer binding site into the viral chromosome upstream E2 promoter. In a second preferred embodiment of such vector the adenovirus genome is deleted of E1 and E4 gene and E2a genes. In a third preferred embodiment of such vector the adenovirus genome  
10 is deleted of E1 and E4 gene and E2b genes.

An essential characteristic of such a "shuttle vector" is the replicating capacity that reproduces a high number of copies per cell once the transcription of the Ad genes has been activated. This is made possible by  
15 the presence in the construct of the inverted terminal repeats (ITRs) of adenovirus in head-tail configuration.

In a preferred embodiment of such vector, the Ad genome is that of the Ad5 serotype, in a second preferred embodiment such vector includes the Ad2 serotype genome.  
20 Combinations with other serotype genomes or any other member of the Adenoviridae family are possible, and might be preferred in some applications.

In a preferred embodiment of such vector the ITRs are those of the Ad5 serotype. In a further preferred  
25 embodiment of such vector the ITRs are those of the Ad2 serotype. Combinations with ITRs of other serotypes or any other member of the Adenoviridae family are possible and might be preferred in some applications.

Eukariotic cells can be transformed with the first  
30 genic unit according to transfection protocols like calcium phosphate method or lipofection or using DNA microinjection. Cells containing the first unit can be selected exploiting the presence on the episome of a selection marker by adding the corresponding antibiotic  
35 to the culture medium. Permissive cells containing the first genic unit in episomal form can support the propagation of an adenoviral vector, in presence of the

- 23 -

viral functions which have been deleted or inactivated from the Ad defective genome present in the first genic unit.

5 A cell line obtained as described above, can be used to insert the second genic unit in which the adenoviral function inactivated in the first genic unit are under tight transcriptional control.

10 The second genic unit can be obtained according to standard recombinant DNA techniques like direct cloning into vectors of DNA fragments obtained by DNA digestion with restriction enzymes, PCR or by homologous recombination technique in E.coli or eukariotic cells.

15 The relevant vectors used for the introduction of the second genic unit contains, accordingly, as characterising elements:

I) the non-structural regions inactivated in the adenoviral genome of the first unit, integrated in the genome of the host cell or present into a "shuttle vector";

20 II) an inducible promoter that be strictly regulable; and optionally,

III) two dimer of insulator sequences flanking the transcriptional unit;

25 IV) regulatory elements such tetracycline-responsive elements.

An essential characteristic of such vector is the capacity of being maintained strictly inactive during the growth step of the cell line, in order to avoid the cytotoxic effect of the viral proteins.

30 In a preferred embodiment of such vector the Ad regions are those of the Ad5 serotype, in a second preferred embodiment of such vector the Ad regions are those of the Ad2 serotype. Combinations with Ad regions of other serotypes or any other member of the Adenoviridae family are possible and might be preferred  
35 in some applications.

In a preferred embodiment of such vector the

- 24 -

inducible promoter consists of an element responding to tetracycline. The regulation of the expression is in this case based on the use of the two regulatory elements tetracycline-controlled reverse transactivator (rtTA)  
5 (Gossen, D. et al. (1995) Science 268:1766-1769) and hybrid transcriptional repressor Tet-KRAB (Deuschle, U. et al. (1995) Mol. Cell. Biol. 15:1907-1914) modified so as to prevent the formation of a rtTA/Tet-KRAB dimer (Freundlieb S., et al. J. Gene Med. 1999; 1:1-13).

10 Preferably, the use of a vector containing a single tetracycline-responsive element in form of bidirectional expression is provided, such that the basal activity be strictly repressed by the TetR-KRAB repressor. In absence of Doxycycline the TetR-KRAB repressor binds strongly to  
15 the tetracycline-responsive element, ensuring a drastic decrease of the basal promoter activity. In presence of Doxycycline, transcription is activated by detachment of Tet-KRAB repressor and by the binding of the rtTA activator to the promoter.

20 Alternatively, the system can be based on a reverse silencer obtained fusing the KRAB domain responsible for the transcriptional repression and the DNA binding domain of rtTA in combination with the direct transactivator tTA. In this second version of the regulation system, the  
25 transcriptional repression takes place cultivating the cells in absence of tetracycline.

Other regulation systems are described in the art, as for instance those based on the use of ligands other than tetracycline like RU486 (Wang, K.E., et al. (1994)  
30 PNAS, 91:8180-8184), ecdysone (No, D. et al. (1996) PNAS 93:3346-3351), rapamycin (Spencer, D.M. et al. (1993) Science 262:1019-1024) and their use can easily be adapted to the present invention. For the purpose of the present invention, any genetic expression regulator  
35 whatsoever may be utilised, as long as it ensures a sufficient regulation and be inducible by use of factors acceptable in the pharmacological practice.

- 25 -

The presence of two DNA insulator dimers, improve the stability of the second genic unit allowing the inducibility thereof. These DNA elements can be derived from chicken  $\beta$ -globin locus and are known to protect a transcriptional unit from constitutive inactivation due to DNA methylation and negative or positive influences derived by the position of insertion in host chromosome.

In another embodiment of the cell of the present invention contain a second genic unit in a stable form wherein the non-structural regions deleted or in any way inactivated in the Ad genome of the first genic unit present in the "shuttle vector" is operatively linked to sequences, preferably genomic, inducibly regulating the expression thereof.

The second genic unit can be contained in one or more vectors and inserted into the cells by transfection techniques, microinjection etc.

A marker of selection, like G418 resistance gene, Hygromycin B resistance gene, puromycin resistance gene, bleomycin resistance gene is generally present in both the units and can be used to select cell-line that stably maintain one or both of said units, in this latter case both starting from a cell containing one of the unit or starting from a cells containing no one of said units, in any case according to the well know technique in the art.

The cell lines obtained after transformation with the second genic unit are characterized by the possibility to express the non structural regions contained therein in a tight controlled fashion. In the case of regulation of non-structural regions using the Tet system, the addition of tetracycline to the culture medium result in a derepression of tet promoter mediated by Tetracycline-induced dissociation of tTS from TetR DNA binding site followed by a full transcription activation due to rtTa binding.

In the preferred embodiments this cell line includes in a stable form one or more vectors comprising the genes



- 26 -

coding for the E1 and E4 or E1, E2 and E4, can complement Ad regions deleted from the "Ad/EBV shuttle vector", of a human Ad virus as described in the second aspect of the present invention. In a preferred embodiment the viral genes are those of the Ad5 serotype and the expression regulation system is based on the use of both the tetracycline-controlled reverse transactivator (rtTA) and of the Tet-KRAB hybrid transcriptional repressor as above-disclosed. However, genetic sequences derived from any other member of Adenoviridae family can be used. In its preferred embodiments, this cell line is preferably the A549 line (human Lung carcinoma, ATCC CLL185) as described in the art, however other cell lines permissive for the adenovirus replication are foreseen in the present invention.

In any of the above described cases the derivation of the helper cell line is carried out on eukaryotic cell line, preferably mammalian, preferably of human origin containing the first genic unit included in a stable episomal form a vector (denominated "shuttle plasmid") as above-disclosed in the first aspect of the present invention.

In its preferred embodiments this cell line is preferably the A549 line (human Lung carcinoma, ATCC CLL185) as it is described in the art, but other cell lines of human origin or not, is included in the scope of the present invention, as long as they are permissive for the adenovirus replication.

The helper cell lines so obtained have been used in a method for the production of adenovirus-derived and helper-dependent vectors, which is characterised by the following steps:

a') cultivation of the aforesaid helper cell line, under conditions apt to decrease expression of genes encoded by the adenovirus regions contained inside said cell, said conditions being the condition known in the art for each promoter herein described, as for example

- 27 -

the conditions described in the examples. When Tet system is used for the transcriptional control, the cell line will be cultivated in absence of tetracycline;

5        b') insertion in said helper cell line of the genomic DNA for a helper-dependent adenovirus by vector DNA transfection or infecting the cell as described (Parks, R. J., L. Chen, M. Anton, U. Sankar, M. A. Rudnicki, and F. L. Graham (1996). Proc. Natl. Acad. Sci. USA 93:13656-13570).

10       c') induction of the expression of the genes encoded by the adenovirus regions contained inside said cell. In the case of Tet controlled transcription by adding doxycycline to the culture medium.

15       A large scale production of a fully-deleted HD adenoviral vector is obtained by serial passaging the vector as already described for first generation vectors (Hitt M.M. et al.1995. Meth. Mol. Genet. 7, 13-30).

20       In a preferred embodiment this method is adopted for the production of helper-dependent adenoviral vectors containing genes coding for the expression of polypeptides of therapeutical interest, preferably for use in gene therapy, preferably for use in human gene therapy.

25       A general description of the present invention has hereto been provided. A more detailed description of some specific embodiments thereof will hereinafter be given with the aid of the following examples, aimed at providing a better understanding of its purposes, characteristics, advantages and operative modes.

30       EXAMPLE 1: Construction of an E1 and E4 expression vectors.

All plasmids can be constructed adopting the standard recombinant DNA techniques.

35       The E1 region of the adenovirus 5 can be obtained by PCR utilizing the viral genomic DNA as substrate, and it can be inserted into the pBI plasmid (Baron, U. et al. (1995) Nucleic Acids Res, 23 (17) 3605-3606) containing a

- 28 -

bidirectional promoter consisting of a single tetracycline-responsive element (TRE) flanked by two cytomegalovirus (CMV) minimal promoters (Clontech) between the restriction sites NotI and SalI, generating the pBI.E1 plasmid. Then pBI.E1 can be modified inserting the DNA coding for the adenovirus E4 region obtained by PCR, between the restriction sites MluI and NheI, thus obtaining the pBI.E1/E4 construct.

EXAMPLE 2: Construction of an E1/E4 expression vectors.

All plasmids can be constructed adopting the standard recombinant DNA techniques.

The E4 ORF6 gene DNA was amplified by PCR using the oligonucleotides 5'-TTATACGCGTGCCACCATGACTACGTCCG-3' and 5'-TTATGCTAGCGCGAAGGAGAAGTCCACG-3' and pFG140 containing Ad5 viral genomic DNA as substrate. Amplified DNA was inserted into the pBI plasmid (Clontech) (Baron, U. et al. (1995) Nucleic Acids Res, 23 (17) 3605-3606) containing a bidirectional promoter consisting of a single tetracycline-responsive element (TRE) flanked by two cytomegalovirus (CMV) minimal promoters, between the restriction sites MluI and NheI, generating the pBI.E4 plasmid. pBI.E4 was modified by inserting between the restriction sites NotI and SalI, the DNA coding for the adenovirus E1 region obtained by PCR, using the oligonucleotides 5'-ATGCGCGGCCGCTGAGTTCCTCAAGAGG-3' and 5'-ATGCGTCGACCAGTACCTCAATCTGTATCTTC-3', finally obtaining the pBI.E1/E4 construct (Fig.1).

Expression vectors for E2a and E2b genes were constructed following the same strategy using plasmid pFG140 to amplify DNA binding protein gene DNA and pVACpol and pVACpTP as templates for polymerase and pre-terminal protein (pTp)cDNA amplification. DBP DNA was cloned into pTRE (Clontech) between restriction sites EcoRI and XbaI. Ad polymerase and pTP were cloned into the same vector or in combination into the bi-directional promoter pBI under Tet operator transcriptional control.

- 29 -

Example 3: Construction of a vector expressing tetracycline controlled transcriptional regulators.

The Tet control system permits regulation of gene activities over a wide range of magnitude in mammalian cell. A transcriptional silencer (tTS) was recently developed by fusing the DNA binding domain of tetracycline repressor with the silencing domain of Kid-1 (Freundlieb S., et al. J.Gene Med. 1999; 1:1-13). tTS and rtTA were combined in a single expression vector as follows. An EcoRI-ClaI DNA fragment containing Tet silencer was isolated from the plasmid pUHS6-1 and inserted downstream the IRES sequence into the vector pIRES-Neo (Clontech) replacing the Neo gene. The new vector pIRES-tTS was modified with the insertion of rtTA gene into the unique EcoRV restriction site downstream the human cytomegalovirus IE promoter, generating pIREStTS/rtTA. In order to introduce a marker of selection to isolate cell clones stably expressing Tet proteins, a puromycin resistance expression cassette obtained from pPUR vector (Clontech) was inserted in the XhoI site of pIREStTS/rtTA generating pIREStTS/rtTApuro (Fig.2).

EXAMPLE 4: Construction of the shuttle plasmid

A 32462 bp DNA fragment containing the whole Adenovirus 5 genome deleted of the E1 region and of the encapsidation signal can be obtained cleaving the plasmid pBHG10 (Bett et al. Proc. Natl Acad Sci. 91:8802-8806; 1994) with the restriction enzymes XbaI and ClaI. The resulting fragment can be inserted in the pCEP4 vector (Invitrogen), containing the replication origin of EBV Ori P and the gene for viral transactivator EBNA-1, between the restriction sites SspBI and BamHI, thus obtaining the plasmid pSC. Then the E4 region of the adenovirus genome can be deleted, eliminating the DNA fragment comprised between nucleotides 32810 and 35620, thus generating plasmid pSCΔE4. Subsequently, pSCΔE4 modifications can be inserted in order to optimize the

- 30 -

vector characteristics. For instance, the reinsertion into the viral genome of sequences from the Ad5 wt E3 region that have been deleted in the context of pBHG10 can improve the expression levels of the gene encoding the virus fiber. In addition, a DNA fragment including multiple binding sites of the tetracycline repressor (tet-O) can be inserted upstream of the transcription starts of the E2 region in order to further attenuate the residual expression of the adenovirus genome as described by Rittner (Rittner K., et al (1997) J. Virol. 71:3307-3311). In this version of the shuttle plasmid pSCAE4, its expression is further attenuated by Tet-KRAB, that binds to the E2 region in absence of tetracycline.

EXAMPLE 5: Construction of the shuttle plasmid

A: Subcloning and modification of E4 region of Ad5

A DNA fragment containing the whole Adenovirus 5 E4 region was obtained cleaving the plasmid pBHG10 (Bett et al. Proc. Natl Acad Sci. 91:8802-8806; 1994) with SpeI and ClaI restriction enzymes. The isolated fragment was ligated in the pBluescript vector (Stratagene), between the restriction sites SpeI and ClaI yielding the plasmid pBSE4. Then pBSE4 was modified by inserting an eptamer of DNA binding sites for the Tet repressor into the unique Pac I restriction site, generating pBSE4-ept. The Tet eptamer DNA was amplified by PCR using the oligonucleotides 5'-CTGATTAATTAAATAGGCGTATCACGAGGCC-3' and 5'-CTGACGATCGCGTACACGCCTACTC-3' and the plasmid pUHD10.3 as DNA template. The Tet binding site was cloned into PacI restriction site of pBSE4, just upstream the E2 promoter. The final goal was the reduction of background expression of E2 promoter exploiting the silencing effect of tetracycline-controlled transcriptional silencer as described by Rittner (Rittner K., et al (1997) J. Virol. 71:3307-3311). Ad5 E4 region present in pBSE4-ept was then eliminated by digestion with MfeI and ClaI restriction enzymes, the vector DNA was gel-purified and ligated to a Tk-Hygromycin B resistance expression

- 31 -

cassette DNA obtained by PCR with the oligonucleotides 5'-AGTGCACAATTGATTTAAATAATCCGCGCGGTGG-3' and 5'-TGCAATCGATCAACGCGGGCATCC-3' using pCEP-4 plasmid DNA as template, generating pBSΔE4. The adenovirus ITRs in head-to-tail configuration were then amplified by PCR using the oligonucleotides 5'-TCGAATCGATACGCGAACCTACGC-3' and 5'-TCGACGTGTCGACTTCTGAAGCGCACACCAAAAACGTC-3' and pFG140 (Microbix) plasmid DNA as template. The Ad ITRs were cloned into the NruI unique site of pBSΔE4, generating pBSΔE4J.

#### B: Insertion of EBV OriP into pLBG40

A DNA fragment containing EBV OriP was isolated from pCEP4 vector by MfeI digestion and subcloned into pLitmus 28 (N.E. Biolabs) digested with EcoRI restriction enzyme. The resulting plasmid plit-OriP was then digested with XbaI to release a 2476 bp DNA fragment containing EBV-OriP that was cloned into the unique XbaI site of pLBG40 plasmid (Recchia, A. et al. 1999 Proc. Natl Acad Sci. 96:2615-2620) yielding pLBG-OriP.

#### C: Costruction of Ad/EBV shuttle plasmids

A shuttle plasmid pSA-1 (Fig.2) that carries a copy of Ad5 genome deleted of E1, E3, E4 and packaging signal, was constructed by substituting the DNA fragment of pLBG-OriP comprises between SfuI and PacI restriction sites with the PacI-ClaI DNA fragment derived from pBSΔE4J.

pSA-1 was further modified by inserting EBNA-1 gene as follows. pREP10 (Invitrogen), a plasmid that contain both elements of EBV latent origin of replication, EBNA-1 and OriP, was digested with XbaI and NheI to eliminate a 429-bp DNA fragment containing SV40 polyA. Plasmid DNA was completely filled in, gel-purified and ligated to generate pREP11. pREP11 was then digested with EcoRI and XhoI to release a DNA fragment containing both EBNA-1 gene and OriP. This DNA fragment was subcloned into pLitmus28 digested with EcoRI and XhoI to obtain pREP12. pREP12 was digested with EcoRI and MluI, gel purified and ligated to the 3627 bp EcoRI-MluI DNA fragment isolated

- 32 -

from pCEP4, generating pREP13. pREP13 was digested with XbaI and NheI to release a DNA fragment with XbaI-compatible ends that contains EBNA-1 and OriP. Finally, this DNA fragment was cloned into pSA-1. digested with XbaI to generate pSA-2.

Example 6. Ad/EBV shuttle plasmids modification

Ad/EBV shuttle plasmids (pSA-1 and pSA-2) were further modified by deleting a DNA sequence corresponding to DNA binding protein (DBP) gene (nucleotides 22443-24032 of Ad5 sequence). The deletion was obtained by homologous recombination in E. coli, following the method described by A.F. Stuart and coworkers (Zhang et al. Nat. Genet. 1998;20:123-128). A DNA fragment containing the Tn5 kanamycin resistance gene (neo) flanked by DNA sequences was obtained by PCR with oligonucleotides 5'-GCGGTTAGGCTGTCCTTCTTCTCGACTGACTCCATGATCTTTTCTGCCTATAGGAGAAGGAATCCCGGC

GGATTGTCTACTCAGGAGAGCG-3' and 5'-AAATGCTTTTATTTGTACACTCTCGGGTGATTATTTACCCCCACCCTTGCCGTCTGC

GCCGTTCTGCAAACCCTATGCTACTCCGTCG-3' consisting of about 60-bp of homology to DBP gene and, at 3' ends PCR primers to amplify neo gene using pGKfrt as template. Linear DNA containing neo gene was used in recombination experiments to delete the DBP gene from Ad/EBV shuttle plasmids. The same method was applied to construct Ad/EBV shuttle plasmids that do not express Ad polymerase gene and preterminal protein. The sequence of the oligonucleotides used to delete the polymerase gene was 5'-ACGGCCTGGTAGGCGCAGCATCCCTTTTCTACGGGTAGCGCGTATGCCTGCGCGGCC

TTCCGGTCTGCAAACCCTATGCTACTCCGTCG-3' and 5'-AGACCTATACTTGGATGGGGGCCTTTGGGAAGCAGCTCGTGCCCTTCATGCTGGTCA

TGTCCCGGCGGATTGTCTACTCAGGAGAGCG-3'. Two pairs of oligonucleotides were used to delete two regions within the the main exon of pTP: 5'-CCGCCTCCCGGTGCGCCGTCGTCGCCGCGTGTCCCCCTCCCCACCGTCCCGGCG

GATTTGTCTACTCAGGAGAGCG-3' and 5'-GATCTCCGCGTCCGGCTCGCTCCACGGTGGCGGCGAGGTCGTTGGAAATGCGTCTGC

- 33 -

AAACCCTATGCTACTCCGTCG-3', 5'-  
TCGACAGAAGCACCATGTCCTTGGGTCCGGCCTGCTGAATGCGCAGGCGGTCTGCAA  
ACCCTATGCTACTCCGTCG-3' and 5'-  
TCGCCCCCGGAGCCCCGGCCACCCTACGCTGGCCCCCTCTACCGCCAGCCGCTCCCGG  
CGGATTTGTCCTACTCAGGAGAGCG -3'.

The same method can be applied to other region of Adenovirus genomic DNA relevant to obtain a reduction of cytotoxic effects produced by viral gene expression in the infected cell.

Example 7. Evaluation of E1/E4 expression

In order to assess the regulation of E1 gene expression in cell producing Tet proteins, HeLa cells were seeded on 6-well plates and transfected with pBI.E1/E4 in combination with pIREStS/rtTA<sub>puro</sub>. The experiment was done in duplicate with and without doxycycline. 48 hours post-transfection HeLa cells were harvested and cell lysates were analyzed by western blot using a monoclonal antibody directed against E1 proteins. 293 cells that constitutively express E1 region were used as positive control.

A leaky expression of E1 proteins was detectable in cells transfected with pBI.E1/E4 alone. As expected, in presence of Tet regulatory factors, we observed a strong expression of E1 proteins induced by doxycycline, while in absence of drug, the expression was non-detectable. This result demonstrates that the expression of Tet silencer actively repress gene activity, thus abolishing background expression. Simultaneous expression of tTS and rtTA did not affect gene induction via rtTA in presence of doxycycline. This result was confirmed by a second experiment in which HeLa cells were infected with a  $\Delta$ E1 Ad vector expressing B-galactosidase and then trasfected with pBI.E1/E4 and pIREStS/rtTA<sub>puro</sub>. 48 hour post-transfection, HeLa cells were harvested and a lysate was obtained by disrupting the cells freeze and thaw. Monolayers of A549 cells were incubated with aliquot of cell lysate and after 24 hour  $\beta$ -gal activity was detected



- 34 -

as described (Parks, R.J. et al 1996; Proc. Natl Acad Sci. 91:8802-8806). Since HeLa are not fully permissive for first generation vector replication, no viral progeny was detected in cell that were only infected, while the  $\Delta E1$  vector was fully complemented in cell transfected with both vectors (pBI.E1/E4 and pIREStTS/rtTApuro) in presence of doxycycline as demonstrated by the detection of lacZ transducing particle in cell lysate. A low  $\beta$ -galactosidase transducing titer was detected after transfection with pBI.E1/E4 as the result of Tet promoter basal activity. On the contrary, no transducing particle were detected in cells maintained in absence of doxycycline after co-transfection of pBI.E1/E4 and pIREStTS/rtTApuro and infected with Ad  $\Delta E1$ -Bgal. This result confirms that a modulation of E1 gene expression can be obtained combining Tet silencer and rtTA activity. In addition tTS expression represses E1 production below the level necessary to detect viral replication of  $\Delta E1$  Ad vector.

Example 8. Complementing function of Ad/EBV shuttle plasmids

In order to test the Ad helper function of Ad/EBV plasmids, the plasmids were co-transfected into A549EBNA and 293EBNA cell lines in combination with the helper dependent Ad plasmid C4E1E4gfp. This vector contains E1 and E4 adenoviral region as well as green fluorescent protein expression cassette. When both plasmids were introduced in the same cell, the expression of E1 and E4 gene activates Ad/EBV plasmid allowing the replication of both vectors but packaging of C4E1/E4gfp DNA only. Two parallel experiments were performed using both cell lines. 72 hours post-transfection, episomal DNA was extracted from one tissue culture dish according to Hirt method. Transfected cells were harvested from the second dish and disrupted by freeze and thaw to obtain a crude cell lysate.

Episomal DNA was digested with HindIII and DpnI

- 35 -

restriction enzymes and analyzed by Southern blot. Filters were hybridized with a hygromycin B DNA probe specific for Ad/EBV plasmid and then, after stripping, re-hybridized with a second DNA probe deriving from C4E1E4gfp that recognizes both plasmids. In parallel, a monolayer of 293 cell was incubated with aliquots of cell lysate to evaluate the production of gfp transducing particles. The results demonstrated that Ad/EBV plasmids replicate in circular form as well as linear form when both Ad (E1/E4) and EBV (EBNA-1) viral transactivator are expressed. In addition, activation of Ad transcriptional program led to C4E1E4gfp DNA replication and packaging into mature virions as demonstrated by the observation of fluorescent gfp expressing cells in the 293 monolayer incubated with cell lysate.

EXAMPLE 9: Construction of a cell line expressing regulation proteins

A549 cells (human Lung carcinoma, ATCC CLL185) expressing both the tetracycline-controlled reverse transactivator (Gossen, D. et al. (1995) Science 268:1766-1769) and the Tet-KRAB hybrid transcriptional repressor (Deuschle, U. et al. (1995) Mol. Cell. Biol. 15:1907-1914) can be obtained by cotransfection of the two plasmids pTet-On (Clontech) and pTetKRAB. Subsequently the cell clones obtained by selection with G-418 antibiotic can be tested to evaluate the expression of both transregulating proteins by the use of any vector in which a reporter gene under control of the Tet operator is inserted.

A first generation adenoviral vector was constructed inserting in the Pac I site of the plasmid pLBG40 an expression cassette containing the luciferase gene placed under control of the Tet operator, thus obtaining the plasmid pLBGluc.

This plasmid includes the entire Adenovirus genome deleted of the E1 and E3 regions and therefore it is infective if inserted by transfection in 293 cells. The

- 36 -

virus (AdLBGluc) contained in the plaques appearing about 10 days p.t. in 293 cells cultivated in monolayer, was expanded, titrated and assayed for luciferase enzyme expression.

5 About  $10^4$  cells of each clone obtained by resistance to G418 can be seeded in 24-well plates and infected with AdLBGluc virus at a moi of 20. The same number of cells was seeded in duplicate on a second plate and cultivated in presence of doxycycline prior to infection. 48 hours  
10 p.i. the cells are harvested and lysated. The expression levels of the luciferase gene were assessed utilizing the natural substrate luciferin. The clones in which the best ratio was observed between the activation of luciferase expression in presence of doxycycline and the basal level  
15 in absence of ligand were selected and expanded. A clone prepared according to this procedure was expanded to further define characteristics of growth, stability and expression levels of the regulation proteins. Therefore, suitable banks of frozen cells was prepared to ensure the  
20 maintenance of a cell line that express the regulation proteins of the transcription rtTA and Tet-KRAB.

EXAMPLE 10: Construction of the E1/E4-inducible cell line

25 The plasmid pBI.E1/E4 (see example 1) can be transfected in the cells of the previously selected clone, together with a plasmid expressing resistance to puromycin antibiotic. The cells are selectable by growth on a medium containing the antibiotic and assayed for their expression of adenovirus early proteins under  
30 control of tetracycline. For this purpose, a second generation adenoviral vector deleted of both the E1 and of the E4 region can be constructed, as it is described in literature (Brough, D.E. et al. (1996) J.Virol. 70:6497-6501). The cell clones obtained by insertion of  
35 the transcriptional unit E1/E4 in the cell can be selected on the basis of their capacity of complementing the helper dependent defective adenoviral vector, thus

- 37 -

allowing its replication. Puromycin-resistant clones can be seeded in 24-well plates in duplicate. Then the cells can be infected with the  $\Delta$ E1/E4 virus and then cultivated with and without addition of doxycycline to the culture medium. In presence of doxycycline the E1 and E4 transcription activation can make cells permissive for viral replication, therefore evidencing the entailed cytopathic effect. The clones, in which the Ad $\Delta$ E1/E4 vector can replicate exclusively in presence of doxycycline, can be expanded and further characterized assessing sustainable production of the defective virus.

Example 11. Construction of an EBNA-1 expressing A549 cell line

An A549 cell line expressing EBNA-1 gene was generated by stable transfection of pEB vector (Ramage, A.D. et al. 1997. Gene 197:83-89). pEB was linearized by MluI restriction and transfected into A549 using Fugene 6 reagent (Boehringer). 72 hours post-transfection A549 cells were split at 1:20 ratio in selective medium containing 600  $\mu$ g/ml of G418. 10 resistant clones were expanded and tested for episomal replication of plasmid pCEP-EBNAdel containing EBV Ori-P and Hygromycin resistance gene expression cassette.

EXAMPLE 12: Construction of the helper cell line

The shuttle plasmid pSCEA4 can be inserted by transfection techniques in the cell line including the E1/E4 inducible transcriptional unit. The resistant cell clones obtained cultivating the transfected cells in presence of the antibiotic hygromycin B can be expanded and further characterized for their capacity to inducibly express the adenovirus genes and to sustain the propagation of an Ad helper-dependent vector. Firstly, the inducible expression of the adenoviral genome can be monitored, assessing the entailed cytopathic effect by cultivating the cells in presence of tetracycline. The production of the adenovirus structural proteins can be quantitatively determined by western blotting and

- 38 -

immunoprecipitation techniques with specific antibodies as already described in literature. The capacity of the cell clones including the episome pSCAE4 of allowing replication of helper-dependent vectors can be studied utilising different vectors containing the reporter genes coding for the Green Fluorescent Protein (GFP) or for the  $\beta$ -galattosidase or any other gene having an easily detectable activity. The cells can be infected with different moi of the helper-dependent virus, then harvested when the cytopatic effect is evident, after tetracycline-induced expression of the adenoviral genome. The virus yield can be determined using the cellular lysate as described by Parks in PNAS 1996. The assessment of the ratio between the number of transducing viral particles produced infecting the packaging cell lines and those present in the viral inoculum used can allow an evaluation of the virus production efficiency in the different clones obtained.

Example 13. Costruction of cell lines containing Ad/EBV shuttle vector

A. A549-EBNA clones containing Ad/EBV shuttle vector

Ad/EBV shuttle plasmid was introduced into A549-EBNA cell line using Fugene-6 transfection reagent (Boehringer) or calcium phosphate method. Ad/EBV plasmid was transfected alone or in combination with pIREStS/rtTA<sub>puro</sub> or pUHS6-1. The co-transfection of Ad/EBV shuttle vector with plasmids expressing the Tet silencer should further reduce leaking of Ad gene expression by repressing E2 promoter. A549-EBNA cells were put into selective medium containing 400  $\mu$ g/ml of G-418 and 200  $\mu$ g/ml of Hygromycin-B 48-72 post-transfection. Isolated Hygromycin-B resistant clones were trasnferred into 24-well plates and expanded.

In order to test A549 Ad/EBV clones for capacity to complement and propagate a helper dependent Ad vector, a new plasmid C4E1E4gfp was constructed. This helper dependent plasmid contains E1 and E4 adenoviral region as

- 39 -

well as green fluorescent protein expression cassette. HDC4E1E4gfp vector was rescued and amplified using 293CRE4 cells as described (Parks, R.J. et al. 1996 Proc. Natl Acad Sci. 93:13565-13570). A purified preparation of

5 HDC4E1E4gfp was used to infect A549 Ad/EBV clones at low multiplicity of infection.

Clones isolated after Ad/EBV co-transfection with pIREStTS/rtTApuro or pUHS6-1 were tested in duplicate with/out 1 µg/ml of doxycycline. Expression of E1 and E4

10 genes allowed activation of Ad transcriptional program only in clones containing an intact copy of Ad/EBV shuttle plasmid. The result was the induction of cytopathic effect (cpe) and HD vector propagation.

B. Construction of different cell lines containing Ad/EBV shuttle vectorII

15

psA-2 incorporates EBNA-1 expression cassette thus is able to replicate in any cell line permissive for episome maintainance mediated by EBV latent origin of replication. It was then utilized to identify new cell

20 lines different from A549EBNA with improved biological properties. A number of different cell line were transfected and hygromycin B resistant clones were isolated and examined as previously described for clones derived from A549EBNA cells.

Example 14. Isolation of a cell clone expressing E1 and E4 proteins in a Tet regulated fashion

25

A549EBNA cells expressing both the tetracycline-controlled reverse transactivator (Gossen, D. et al. (1995) Science 268:1766-1769) and the tTS transcriptional silencer (Deuschle, U. et al. (1995) Mol. Cell. Biol. 15:1907-1914; Freundlieb S., et al. J.Gene Med. 1999; 1:1-13) was obtained transfection of pIREStTS/rtTApuro. Subsequently the cell clones obtained by selection with puromycin antibiotic were tested to evaluate the

30 expression of both transregulating proteins by the use of any vector in which a reporter gene under control of the Tet operator is inserted.

35

- 40 -

A first generation adenoviral vector was constructed inserting in the XbaI site of the plasmid pLBG40 an expression cassette containing the luciferase gene placed under control of the Tet operator, That was obtained by PvuII digestion of pABS-Tetluc, thus obtaining the plasmid pLBGTetluc.

This plasmid includes the entire Adenovirus genome deleted of the E1 and E3 regions and therefore it is infective when transfected in 293 cells. Isolated plaques were visible 10 days after 293 transfection. Three plaques were picked and analyzed by Hind III digestion following the method described by Graham, F.L. and co-workers 1995, Methods in Molecular Genetics 7:13-30. All three plaques showed the correct restriction pattern. One viral isolate was expanded, titrated and assayed for luciferase enzyme expression.

About  $10^4$  cells of each clone obtained by resistance to puromycin were seeded in duplicate in 24-well plates and infected with AdLBGluc virus at a moi of 20. One plate was cultivated in presence of doxycycline prior to infection. The cells were harvested 48 hours p.i. and lysated. The expression levels of the luciferase gene were assessed utilizing the natural substrate luciferin. The clones in which the best ratio is observed between the activation of luciferase expression in presence of doxycycline and the basal level in absence of ligand were selected and expanded. A clone prepared according to this procedure was expanded to further define characteristics of growth, stability and expression levels of the regulation proteins. Therefore, suitable banks of frozen cells was prepared to ensure the maintenance of a cell line that express the regulation proteins of the transcription rtTA and Tet-KRAB.

EXAMPLE 15: Construction of the E1/E4-inducible cell line

The plasmid pBI.E1/E4 (see example 1) was transfected in the A549EBNA cells together with

- 41 -

pIREStTS/rtTApuro. The cells were selected by growth on a medium containing the antibiotic and assayed for their expression of adenovirus early proteins under control of tetracycline. For this purpose, a second generation adenoviral vector deleted of both the E1 and of the E4 region (Krougliak, V. et al 1995 Hum. Gene Ther. 6:1575-1586) was obtained from F.L. Graham and used to screen for positive clones. The cell clones obtained by insertion of the transcriptional unit E1/E4 in the cell were selected on the basis of their capacity of complementing the helper dependent defective adenoviral vector, thus allowing its replication. Puromycin-resistant clones were seeded in 24-well plates in duplicate. Then the cells were infected with the  $\Delta$ E1/E4 virus and then cultivated with and without addition of doxycycline to the culture medium. In presence of doxycycline the E1 and E4 transcription activation can make cells permissive for viral replication, therefore evidencing the entailed cytopathic effect. Viral titers were evaluated by PCR using the TaqMam method. The clones, in which the Ad $\Delta$ E1/E4 vector can replicate exclusively in presence of doxycycline, were expanded and further characterized assessing sustainable production of the defective virus. The same procedure was followed to obtain A549EBNA clones expressing E2 genes under tetracycline control. The clones obtained were screened using Ad vectors deleted of the corresponding E2 genes.

EXAMPLE 16: Construction of the helper cell line and HD propagation

The shuttle plasmid pSA-1 was inserted by standard transfection techniques in the cell line including the E1/E4 inducible transcriptional unit and Tet proteins. Several resistant clones were obtained by splitting the cells 48 hours post-transfection and cultivating it in a selective medium containing also Hygromycin B at a concentration of 200  $\mu$ g/ml. Resistant clones were expanded and further characterized for their capacity to



- 42 -

inducibly express the adenovirus genes and to sustain the propagation of an Ad helper-dependent vector. Firstly, the inducible expression of the adenoviral genome was monitored, assessing the entailed cytopathic effect by cultivating the cells in presence of tetracycline. The induction of the adenovirus structural protein production was quantitatively determined by western blotting and immunoprecipitation techniques with specific antibodies. The capacity of the cell clones including the episome pSA-1 of allowing replication of helper-dependent vectors was studied utilising different vectors containing the reporter genes coding for the Green Fluorescent Protein (GFP) or for the  $\beta$ -galactosidase or any other gene having an easily detectable activity. The cells were infected with different moi of the helper-dependent virus, then harvested when the cytopathic effect is evident, after tetracycline-induced expression of the adenoviral genome. The virus yield was determined using the cellular lysate to infect 293 cell monolayer. The assessment of the ratio between the number of transducing viral particles produced infecting the packaging cell lines and those present in the viral inoculum was used to evaluate the virus production efficiency in the different clones obtained.

The same procedure was followed to derive packaging cell lines with the modified versions of Ad/EBV shuttle plasmid combining different deletion of early genes including E2 genes.

- 43 -

REFERENCES

- Baron, U. et al. (1995) Nucleic Acids Res, 23 (17) 3605-3606
- Brough, D.E. et al. (1996) J.Virol. 70:6497-6501
- 5 - Bett et al. Proc. Natl Acad Sci. 91:8802-8806; 1994
- Calos MP. 1996 Trends Genet 12: 463-466
- Calos MP, (1998) Proc Natl Acad Sci USA 95:4084
- Deuschle, U. et al. (1995) Mol. Cell. Biol. 15:1907-1914
- 10 - Englehardt et al. Proc. Natl Acad Sci. 91:6196-6200; 1994
- Freundlieb S., et al. J.Gene Med. 1999; 1:1-13
- Gossen, D. et al. (1995) Science 268:1766-1769
- Hitt M.M. et al.1995. Meth. Mol. Genet. 7, 13-30.
- 15 - Hitt M.M. et al.1997. Advances in Pharmacol:40, 137-206
- Horvitz, "Adenoviridae and their replication" in Virology, Field and Knipe, ed. Raven Press, NY; 1990; pages 1679-1740
- 20 - Kozarsky et al. J. Biol. Chem. 269:1-8; 1994
- Krougliak,V. et al 1995 Hum. Gene Ther. 6:1575-1586
- No, D. et al. (1996) PNAS 93:3346-3351
- Parks, R. J., L. Chen, M. Anton, U. Sankar, M. A. Rudnicki, and F. L. Graham (1996). Proc. Natl. Acad. Sci. USA 93:13656-13570.
- 25 - Sambrook J.,Fritsch EF. and Maniatis T.- (1989)Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
- Spencer, D.M. et al.(1993) Science 262:1019-1024
- 30 - Wang, K.E., et al. (1994) PNAS, 91:8180-8184
- Yang et al. Proc. Natl Acad Sci. 91:4407-4411; 1994

- 44 -

CLAIMS

1. Cells for the production of helper dependent adenoviral vectors, including at least the following genic units:

5       - a first genic unit comprising an adenovirus defective genome having the inverted terminal repeats in head-to-tail configuration, the encapsidation signal inactivated, and at least one of the non-structural regions inactivated;

10       - a second genic units comprising at least one inducible promoter and at least one of the regions inactivated in the first genic unit, said regions being under the control of said inducible promoter;

15       whereby following the activation of the inducible promoter of the second genic unit and the infection of the cells with said helper dependent adenoviral vectors, the first genic unit and the second genic unit enable the production of said helper dependent defective adenoviral in said cells in absence of helper.

20       2. Cells according to claim 1, wherein the first genic unit is integrated in the genome of the cells and has at both the extremities Inverted terminal Repeats in head-to-tail configuration.

25       3. Cells according to claim 1, wherein the first genic unit is included in an episomal unit including an element enabling the replication of said episomal unit in a low number of copies.

30       4. Cells according to claim 3, wherein said element enabling the replication of said episomal unit is the origin of replication of a virus.

5. Cells according to claim 4, wherein the gene coding for the activating factor of said origin of replication is further included in the episomal unit.

35       6. Cells according to claim 4, wherein the gene coding for the activating factor of said origin of replication is integrated in the genome.

7. Cells according to any of claim 4 to 6, wherein

- 45 -

said virus is Epstein-Barr virus, the origin of replication is OriP and the activating factor is EBNA-1.

8. Cells according to any of claims from 1 to 7, wherein the encapsidation signal of the adenovirus defective genome of the first unit is inactivated by total or partial deletion.

9. Cells according to any of claims from 1 to 8, wherein the non-structural regions of the adenovirus defective genome of the first unit is inactivated by total or partial deletion.

10. Cells according to any of claim 1 to 9, wherein the inactivated regions of the first unit are selected from the group consisting of E1, E2 and E4.

11. Cells according to claim 10, wherein said regions are E1 and E4.

12. Cells according to claim 10, wherein said regions are E1, E4 and E2A.

13. Cells according to claim 10, wherein said regions are E1, E4 and E2b polymerase.

14. Cells according to claim 10, wherein said regions are E1, E4 and E2b preterminal protein (PTP).

15. Cells according to any one of claims 1 to 14 wherein the viral regions of the first genic unit is operatively linked to at least one regulatory element enabling the tight control of the expression of said regions.

16. Cells according to any one of claims 1 to 15 wherein the promoter on the second genic unit is the tetracycline operator.

17. Cells according to any one of claims 1 to 16 wherein the viral regions in the second genic unit are operatively linked to elements regulating the expression of said regions.

18. Cells according to any one of claims 1 to 17 wherein the adenovirus defective genome of the first unit is totally or partially constituted by the genome of a human adenovirus.

- 46 -

19. Cells according to claim 18, wherein said adenovirus defective genome of the first unit is totally or partially constituted by the genome of at least one of the human adenoviruses Ad2 and Ad5.

5        20. Cells according to any of claims 1 to 19, wherein the viral regions of the second genic unit, are totally or partially constituted by the viral regions of a human adenovirus.

10       21. Cells according to claim 20, wherein said viral regions of the second genic unit, are totally or partially constituted by the viral regions of at least one of the human adenoviruses Ad2 and Ad5.

15       22. Cells for the production of helper dependent adenoviral vectors including the first genic unit as defined in any of the claims 1 to 21.

23. Cells for the production of helper dependent adenoviral vectors, including the second genic unit as defined in any of the claims 1 to 21.


20       24. The cells according to any of claims 1 to 23, wherein said cells are mammalian cells.

25       25. The cells according to claim 24, wherein said mammalian cells are human cells.


26. Compositions comprising helper dependent adenoviral vectors and a vehicle or a carrier, characterised in that said composition is free of contaminating helper viruses.

30       27. Use of the cells according to anyone of the claims from 1 to 25, for the production of helper dependent adenoviral vectors including at least a gene of interest.


A)



B)



C)



D)





Fig. 1

**Fig. 2**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification <sup>7</sup> : C12N 15/86, 5/10, C07K 14/075	A3	(11) International Publication Number: WO 00/28060 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/IT99/00356 (22) International Filing Date: 8 November 1999 (08.11.99) (30) Priority Data: RM98A000694 6 November 1998 (06.11.98) IT (71) Applicant (for all designated States except US): ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE [IT/IT]; P. Angeletti S.p.A., Via Pontina Km. 30,600, I-00040 Pomezia (IT). (72) Inventor; and (75) Inventor/Applicant (for US only): COLLOCA, Stefano [IT/IT]; Via Peretti, 22, I-00153 Roma (IT). (74) Agents: BAZZICHELLI, Alfredo et al.; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published With international search report.  (88) Date of publication of the international search report: 5 October 2000 (05.10.00)

## (54) Title: CELLS FOR THE PRODUCTION OF HELPER DEPENDENT ADENOVIRAL VECTORS


## (57) Abstract

The present invention relates to cells for the production of helper dependent adenoviral vectors, including at least the following genic units: a first genic unit comprising an adenovirus defective genome having the inverted terminal repeats in head-to-tail configuration, the encapsidation signal inactivated, and at least one of the non-structural regions inactivated; a second genic units comprising at least one inducible promoter and at least one of the regions inactivated in the first genic unit, said regions being under the control of said inducible promoter; whereby following the activation of the inducible promoter of the second genic unit and the infection of the cells with said helper dependent adenoviral vectors, the first genic unit and the second genic unit enable the production of said helper dependent defective adenoviral in said cells in absence of helper.


A)




B)



C)



D)





**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 99/00356

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/86 C12N5/10 C07K14/075

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 13510 A (PARKS ROBIN ; CHEN LIANE (CA); GRAHAM FRANK L (CA)) 2 April 1998 (1998-04-02) page 7, line 33 -page 9, line 36; claims 1,2,6,9,16,19 page 25, line 2133 ---	1,2,8,9, 18-27
A	FR 2 738 575 A (CENTRE NAT RECH SCIENT) 14 March 1997 (1997-03-14)  claims 1-7,9,10,15-22 ---	1,10,11, 17-21, 23-27
A	WO 98 13499 A (CIBA GEIGY AG ; SCRIPPS RESEARCH INST (US); MEMEROW GLEN R (US); VO) 2 April 1998 (1998-04-02) the whole document --- -/--	1,9-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 June 2000

Date of mailing of the international search report

06/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

# INTERNATIONAL SEARCH REPORT

Inte. onal Application No  
PCT/IT 99/00356

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 00 12740 A (AMALFITANO ANDREA ;HU HUIMIN (US); UNIV DUKE (US); CHEN YUAN TSONG) 9 March 2000 (2000-03-09) claims 1-3,78-81,85,207-213,217,218,223-228,231,2 32 -----</p>	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 99/00356

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9813510 A	02-04-1998	EP 0938579 A	01-09-1999
FR 2738575 A	14-03-1997	AU 717253 B	23-03-2000
		AU 4544396 A	07-08-1996
		BR 9606971 A	04-11-1997
		CA 2210168 A	25-07-1996
		CZ 9702306 A	15-10-1997
		EP 0805868 A	12-11-1997
		FI 973055 A	18-07-1997
		WO 9622378 A	25-07-1996
		HU 9702404 A	28-04-1998
		JP 11504502 T	27-04-1999
		NO 973332 A	18-07-1997
		SK 99097 A	04-02-1998
WO 9813499 A	02-04-1998	AU 4624197 A	17-04-1998
		EP 0937150 A	25-08-1999
WO 0012740 A	09-03-2000	AU 5694299 A	21-03-2000